Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore. This facility, which employs an ‘industry first’ modular concept, is designed to offer flexible manufacturing capabilities for the production of next-generation vaccines and biological medicines.
Investment and Capabilities of Modulus
The SGD 800 million (USD 558 million) investment in Modulus positions it as a leading-edge facility in the pharmaceutical industry. With the ability to manufacture up to four vaccines or biopharmaceuticals at the same time, Modulus is set to enhance Sanofi’s global manufacturing capacity and contribute to the development and supply of innovative healthcare solutions.
Timeline for Full Operation and Job Creation
Modulus is expected to be fully operational by mid-2026, marking a significant milestone in Sanofi’s expansion plans. The facility will also create 200 technical positions, providing valuable employment opportunities in Singapore and contributing to the local economy.-Fineline Info & Tech
